Talk:Alpelisib
Jump to navigation
Jump to search
| This is the talk page for discussing improvements to the Alpelisib article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Alpelisib.
|
Study found that alpelisib treated mice had a 10% longer median lifespan than those in the control group
This is a single study & a primary source, therefore it does not meet WP:MEDRS criteria for inclusion into this article. However, going forward, please look for reviews or surveys of the literature that may discuss this. This article is available through the Wikipedia Library.
- Hedges, C. P.; Shetty, B.; Broome, S. C.; MacRae, C.; Koutsifeli, P.; Buckels, E. J.; MacIndoe, C.; Boix, J.; Tsiloulis, T.; Matthews, B. G.; Sinha, S.; Arendse, M.; Jaiswal, J. K.; Mellor, K. M.; Hickey, A. J. R.; Shepherd, P. R.; Merry, T. L. (2023-01-23). "Dietary supplementation of clinically utilized PI3K p110α inhibitor extends the lifespan of male and female mice". Nature Aging. Springer Science and Business Media LLC. doi:10.1038/s43587-022-00349-y. ISSN 2662-8465.